Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The inhibitor prevents the therapy from working, which makes it harder to avoid an episode of bleeding.
As per DelveInsight’s analysis, in 2022, the total treated prevalent population of hemophilia B in the US was approximately 4K. As per the estimates it can be observed that moderate hemophilia B cases are higher in number than mild and severe cases ...
